Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Hong Jae Chon, MD/PhD
CHA University Bundang Medical Center
Principal Investigator - Keun Wook Lee, MD/PhD
Seoul National University Bundang Hospital
Principal Investigator - Myung-Ah Lee, MD/PhD
The Catholic University of Korea
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cha University Bundang Medical Center
Seongnam, South Korea
Recruiting - Seoul National University Bundang Hospital
Seongnam, South Korea
Recruiting - the Catholic University of Korea Seoul St. Mary'S Hospital
Seoul, South Korea
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Oct 2023
- Primary completion
- 31 Oct 2024
- Completion
- 31 Jan 2025
- Last update posted
- 23 Feb 2024
- Registered enrollment
- 30
- Registry id
- NCT06075849
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.